The spotlight was on OraSure Technologies this summer, when the FDA approved its OraQuick HIV testing kit for in-home use. The test analyzes oral fluid as opposed to blood samples, requiring nothing more than a quick mouth-swab and less than a 30-minute wait time for results. Clinicians have used the kit for years, but as of July it was approved for consumer purchase as well.
OraSure is launching the kit this month, and investors should be closely watching the product's sales in upcoming quarters. Health-care analysts Brenton Flynn and Max Macaluso discuss this catalyst.
One thing that's for sure is that a lot is riding on this product for OraSure. Keep in mind that while you can make huge gains investing in the biotech space, you can also suffer from huge losses. The best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you retire well and also reveal winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.